{"id":"W4390097833","doi":"10.1093/infdis/jiad580","title":"Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials","year":2023,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Research and Development; ViiV Healthcare","keywords":"Rilpivirine; Pharmacokinetics; Pharmacology; Medicine; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006586436,0.0007297116,0.001667131,0.000390404,0.0004663817,0.001173767,0.0005182005,0.0006795874,0.00205698],"category_scores_gemma":[0.003771486,0.0003571184,0.001635915,0.0007477104,0.0004510642,0.0007619518,0.0004546809,0.001288441,0.0002439238],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005360436,"about_ca_system_score_gemma":0.001314206,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000711823,"about_ca_topic_score_gemma":0.002885445,"domain_scores_codex":[0.9971718,0.001944708,0.0002481507,0.0002186118,0.0002102704,0.0002064181],"domain_scores_gemma":[0.9972881,0.0009599206,0.0008766371,0.000164261,0.0002342374,0.0004768537],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8585124,0.003602269,0.03535738,0.001706723,0.007647674,0.000121647,0.0002996231,0.001294694,0.009847727,0.0002602497,0.003944824,0.07740482],"study_design_scores_gemma":[0.5253171,0.1981115,0.240297,0.0008223556,0.01355097,0.0005518576,0.0004227778,0.004048454,0.004565882,0.002099578,0.01004955,0.0001629926],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9776475,0.01781068,0.000568641,0.0005156382,0.00007754454,0.0006651763,0.001121703,0.00004138277,0.001551682],"genre_scores_gemma":[0.9922,0.002991396,0.0009018819,0.0006042007,0.0001210964,0.001228496,0.001511553,0.00002103176,0.0004203813],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006586436,"threshold_uncertainty_score":0.03483278,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02278962211361726,"score_gpt":0.3417462502474167,"score_spread":0.3189566281337994,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}